SCHEMBL1509488

SCHEMBL1509488

CN1CCN(CCc2ccc(NC(=O)c3ccc4[nH]c(-c5nc6ccccc6[nH]5)nc4c3)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPSE Q9Y251 5/20 0.52
ACHE P22303 1/20 0.51
HDAC3 O15379 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
POLB P06746 3/20 0.49
KDM4E B2RXH2 3/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
MAPT P10636 2/20 0.49
RAB9A P51151 2/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
CHEK1 O14757 1/20 0.49
CDK1 P06493 1/20 0.49
MMP2 P08253 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1509489 0.94 HDAC3 (0.57) HPSEACHEHDAC3HDAC1HDAC2
SCHEMBL14090603 0.84 HDAC6 (0.46) HPSEHDAC3HDAC1HDAC2HDAC8
SCHEMBL12833894 0.83 ABCG2 (0.49) HPSEHDAC3HDAC1HDAC2HDAC8
SCHEMBL14090429 0.83 DDR2 (0.46) HPSEHDAC3HDAC1HDAC2HDAC8
SCHEMBL14090195 0.83 AMY1A (0.46) HPSEHDAC3HDAC1HDAC2HDAC8
SCHEMBL14090435 0.83 ADORA2A (0.49) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL14090399 0.82 KIT (0.43) HPSEHDAC3HDAC1HDAC2HDAC8
SCHEMBL14090436 0.82 ALDH1A1 (0.47) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL14091421 0.82 HDAC3 (0.49) ACHEHDAC3HDAC1HDAC2HDAC8
SCHEMBL14090434 0.82 MEN1 (0.50) HPSEHDAC3HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629147-B2 Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders CHEMBRIDGE CORPORATION (US) 2014-01-14 US disclosed
EP-2298770-A1 Heterocyclic compounds as TrkA modulators ChemBridge Corporation (US) 2011-03-23 EP disclosed